# Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)

Study · id `cardio:ct-nct03566693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03566693](<https://clinicaltrials.gov/study/NCT03566693>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03566693

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

## Technical summary

Registry record NCT03566693. Randomized; no masking; primary purpose treatment. Start 2018-07-30 (actual); primary completion 2021-01-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 176 participants (enrolled count; ClinicalTrials.gov record NCT03566693, source copy `cardio:ctgov-nct03566693-2021-04-21`, retrieved 2026-10-26)
- Started: 2018-07-30 (actual) (ClinicalTrials.gov record NCT03566693, source copy `cardio:ctgov-nct03566693-2021-04-21`, retrieved 2026-10-26)
- Primary completion: 2021-01-04 (actual) (ClinicalTrials.gov record NCT03566693, source copy `cardio:ctgov-nct03566693-2021-04-21`, retrieved 2026-10-26)
- Completion: 2021-01-04 (actual) (ClinicalTrials.gov record NCT03566693, source copy `cardio:ctgov-nct03566693-2021-04-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03566693, source copy `cardio:ctgov-nct03566693-2021-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03566693-2021-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
- Acronym: MOBILE
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Dexcom G6 CGM System
- Intervention (Device): Blood glucose meter
- Lead sponsor: DexCom, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Jaeb Center for Health Research
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: DexCom, Inc. (`cardio:org-dexcom-inc`)
- Registry lists this organization as a collaborator: Jaeb Center for Health Research (`cardio:org-jaeb-center-for-health-research`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial (`cardio:pubmed-34077499`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring (`cardio:pubmed-34704817`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study (`cardio:pubmed-41192933`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0c261b06792d1acc83cf773cde5c69157076158bff307b88042d9d978cc26ad8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
